Suven Pharmaceuticals Limited (SUVENPHAR) - Total Liabilities

Latest as of March 2025: Rs11.91 Billion INR ≈ $128.81 Million USD

Based on the latest financial reports, Suven Pharmaceuticals Limited (SUVENPHAR) has total liabilities worth Rs11.91 Billion INR (≈ $128.81 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Suven Pharmaceuticals Limited equity growth rate to track the company's year-over-year net asset growth rate.

Suven Pharmaceuticals Limited - Total Liabilities Trend (2019–2025)

This chart illustrates how Suven Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. See Suven Pharmaceuticals Limited free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Suven Pharmaceuticals Limited Competitors by Total Liabilities

The table below lists competitors of Suven Pharmaceuticals Limited ranked by their total liabilities.

Company	Country	Total Liabilities
PJT Partners Inc NYSE:PJT	USA	$634.06 Million
Cousins Properties Incorporated NYSE:CUZ	USA	$4.55 Billion
KONINKLIJKE VOP.UNSP.ADR F:VPK	Germany	€3.54 Billion
Tauron Polska Energia S.A. WAR:TPE	Poland	zł26.20 Billion
Asia Commercial Bank VN:ACB	Vietnam	₫931.33 Trillion
Atmus Filtration Technologies Inc. NYSE:ATMU	USA	$1.44 Billion
Novanta Inc F:1GSN	Germany	€704.34 Million
Andon Health Co Ltd SHE:002432	China	CN¥8.08 Billion

Liability Composition Analysis (2019–2025)

This chart breaks down Suven Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SUVENPHAR market cap.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.43	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.70	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.39	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Suven Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Suven Pharmaceuticals Limited (2019–2025)

The table below shows the annual total liabilities of Suven Pharmaceuticals Limited from 2019 to 2025.

Year	Total Liabilities	Change
2025-03-31	Rs11.91 Billion ≈ $128.81 Million	+485.53%
2024-03-31	Rs2.03 Billion ≈ $22.00 Million	-11.77%
2023-03-31	Rs2.31 Billion ≈ $24.93 Million	-23.76%
2022-03-31	Rs3.02 Billion ≈ $32.70 Million	+2.98%
2021-03-31	Rs2.94 Billion ≈ $31.76 Million	-10.48%
2020-03-31	Rs3.28 Billion ≈ $35.48 Million	+70.21%
2019-03-31	Rs1.93 Billion ≈ $20.84 Million	--

About Suven Pharmaceuticals Limited

NSE:SUVENPHAR India Drug Manufacturers - Specialty & Generic

Market Cap

$4.40 Billion

Rs406.97 Billion INR

Market Cap Rank

#3849 Global

#173 in India

Share Price

Rs1063.80

Change (1 day)

+0.00%

52-Week Range

Rs1063.80 - Rs1063.80

All Time High

Rs1334.20